Notwithstanding promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These companies are often building obstacles to coverage, including steep price requirements and PA that restrict patient availability. Marke… Read More